Charles Russell Speechlys advises Kreos and SVB on $70m private placement for AIM listed Mereo BioPharma Group plc
Charles Russell Speechlys has advised long-standing clients, Silicon Valley Bank (SVB) & Kreos Capital V (Expert Fund) LP (Kreos) on a $70m private placement for one of their investee companies, Mereo BioPharma Group plc (Mereo).
Mereo BioPharma is a clinical stage UK-based biopharmaceutical company listed on the AIM market of the London Stock Exchange. It focuses on the development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare diseases.
The net proceeds from the fundraising will be used primarily to fund clinical development activities of the Company’s lead product candidates and for general corporate purposes.
The team at Charles Russell Speechlys was led by Corporate Partner Chris Putt and comprised Associate Jun Park.
